Welcome to chemicalbook!
400-158-6606
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

ChemicalBook > Product Catalogue >Biochemical Engineering >Saccharides >Oligosaccharides >Fondaparinux sodium

Fondaparinux sodium

Fondaparinux sodium Structure
  • ₹0
  • Product name: Fondaparinux sodium
  • CAS: 114870-03-0
  • MF: C31H43N3O49S8.10Na
  • MW: 1728.08
  • EINECS:686-283-7
  • MDL Number:MFCD06794972
  • Synonyms:Methyl O-2-Deoxy-6-O-sulfo-2-(sulfoaMino)-α-D-glucopyranosyl-(14)-O-β- D-glucopyranuronosyl-(14)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoaMino)-α-D-glucopyranosyl-(14)-O-2-O-sulfo-α-L-idopyranuronosyl-(14)-2-deoxy-2-(sulfoaMino)-α-D-glucopyranoside 6-(Hydrogen Sulfate) DecasodiuM Salt;Fondaparinux SodiuM Identification;Fondaparinux sodium N-4;Fondaparinux sodium, >=98%;decasodium (2R,3S,4S,5R,6R)-3-[(2R,3R,4R,6R)-5-[(2R,3R,4S,5S,6S)-6-carboxylato-5-[(2R,3R,4R,5S,6R)-4,5-dihydroxy-3-(sulfonatoamino)-6-(sulfonatooxymethyl)oxan-2-yl]oxy-3,4-dihydroxy-oxan-2-yl]oxy-3-(sulfonatoamino)-4-sulfonatooxy-6-(sulfonatooxymethyl)oxan-2-yl]oxy-4-hydroxy-6-[(2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-5-sulfonatooxy-oxane-2-carboxylate;Fondaparinux sodium;Arixtra (tn);D01844
Manufacturer Product number Product description Packaging Price Updated Buy

Properties

Melting point :>209°C (dec.)
alpha :D23 +48° (c = 0.61 in water)
storage temp. :2-8°C
solubility :Water
form :Solid
color :White to Off-White
InChIKey :XEKSTYNIJLDDAZ-UWCYYFDCNA-D

Safety Information

Symbol(GHS): GHS hazard pictograms
Signal word: Warning
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
H332 Harmful if inhaled Acute toxicity,inhalation Category 4 Warning GHS hazard pictograms P261, P271, P304+P340, P312
Precautionary statements:
P261 Avoid breathing dust/fume/gas/mist/vapours/spray.
P271 Use only outdoors or in a well-ventilated area.
P304+P340 IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P312 Call a POISON CENTER or doctor/physician if you feel unwell.

Description

Fondaparinux sodium was first introduced in the US for prophylaxis of deep vein thrombosis which may lead to pulmonary embolism following major orthopaedic surgery. Fondaparinux is the first of a new class of antithrombic agents distinct from low molecular weight heparin (LMWH) and heparin. This entirely synthetic molecule is a copy of the heparin pentasaccharide sequence, the shortest fragment able to catalyze antithrombin lllmediated inhibition of factor Xa thereby inhibiting thrombin generation without antithrombin action. Fondaparinux does not display significant effects on coagulation tests (such as activated partial thromboplastin time and prothrombin time), does not bind to platelet factor 4 or promote heparin-induced thrombocytopenia. In phase III studies, fondaparinux significantly reduced the incidence of thromboembolism following orthopedic surgery, with an overall risk reduction of 50% in comparison to the LMWH, enoxaparin. Following subcutaneous administration, fondaparinux has a nearly complete bioavailability, a rapid onset of action, a prolonged half-life (17.2 h) enabling once daily dosing and is not metabolized preceeding renal excretion. The drug appears to be generally safe, with haemoragic complications either comparable to or higher than those for LMWH.

Related product price